Brauner S, Eriksson-Dufva A, Hietala MA, et al. - Researchers performed this retrospective cohort study with prospectively collected data on a county-based community sample at Karolinska University Hospital, Stockholm, Sweden to evaluate rituximab in refractory and new-onset generalized myasthenia gravis and rituximab vs conventional immunotherapy in new-onset disease. Rituximab seemed to perform better if started early after the onset of generalized symptoms in this cohort study of 72 patients exposed to rituximab early or later in the myasthenia gravis disease course and controls receiving conventional immunotherapy. Findings suggested that early rituximab treatment may be linked to improved treatment outcomes and may be considered earlier in the treatment algorithms for patients with new-onset generalized myasthenia gravis. Compared with conventional therapies, rates of treatment discontinuation due to adverse events were lower with rituximab. A placebo-controlled randomized trial is warranted to corroborate these findings.